Report
Michael Waterhouse
EUR 147.86 For Business Accounts Only

Akorn Posts Decent Quarter, But Underlying Issues Raise Red Flags

Akorn reported third-quarter revenue and EPS slightly above our expectations, but we’re becoming increasingly concerned with some of underlying factors in the company’s performance. In particular, a price increase on one the firm’s largest products, ephedrine sulfate, combined with volume growth across the portfolio offset mid-single-digit pricing pressure on other products. Gross margin also slipped to about 60%, down from the roughly 61% range seen in previous quarters, that management attribu...
Underlying
Akorn Inc.

Akorn is a generic pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, branded as well as private-label over-the-counter consumer health products and animal health pharmaceuticals. The company's segments include: Prescription Pharmaceuticals, which primarily consists of generic and branded prescription pharmaceuticals in a variety of dosage forms including sterile ophthalmics, injectables and inhalants and non-sterile oral liquids, topicals, nasal sprays and otics; and Consumer Health, which primarily consists of branded and private-label over-the-counter products and animal health products dispensed by veterinary personnel.

Provider
Morningstar
Morningstar

Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.

Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.

We have operations in 27 countries.

Analysts
Michael Waterhouse

Other Reports on these Companies
Other Reports from Morningstar

ResearchPool Subscriptions

Get the most out of your insights

Get in touch